Differential effects of vascular growth factors on arterial and venous angiogenesis

John Blebea, Jonathan Hien Vu, Shahin Assadnia, Patricia McLaughlin, Robert Atnip, Ian Zagon

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective: Angiogenesis, the development of new blood vessels, has become an area of increased interest for both scientific and clinical application purposes. Proangiogenic agents, such as vascular endothelial growth factor (VEGF) and naltrexone, have been shown to effectively induce new blood vessel growth. Other growth factors, such as the endogenous opioid growth factor (OGF; [Mct5]-enkephalin) and retinoic acid, are inhibitors of angiogenesis. The differential effects on veins and arteries, however, by any vascular growth factor, have not previously been investigated. Methods: The chick chorioallantoic membrane (CAM) assay was used for the in vivo quantitation of angiogenesis. After 3 days of incubation, fertilized chick embryos were explanted, and a 3.2-mm methylcellulose disk containing either the known angiogenic stimulators VEGF (0.2 μg, 1.0 μg) or naltrexone (0.1 μg, 5.0 μg), or the angiogenic inhibitors OGF (1.0 μg, 5.0 μg) or retinoic acid (1.0 μg) was placed onto the CAM surface. An equal volume of distilled water served as a control. After 2 days of growth, the CAM arteries and veins were identified, and images were obtained with a digital camera. Quantitative analysis of angiogenesis was performed on a 100-mm2 area surrounding the applied disk, and the number and length of the veins and arteries were measured. Results: The angiogenic stimulators VEGF and naltrexone markedly increased both the total number and length of all blood vessels as compared with control values. The mean length of blood vessels decreased, suggesting the induction of new vessel growth. VEGF and naltrexone proportionately increased vein and arterial angiogenesis, maintaining artery/vein ratios for vessel number and length that were unchanged compared with controls. The angiogenic inhibitors, OGF and retinoic acid, notably decreased the total number and length of blood vessels in the CAM preparations. However, these compounds had a disproportionately greater inhibitory effect on arterial angiogenesis as reflected in decreased artery/vein ratios for vessel number and length. Conclusions: The angiogenic stimulators VEGF and naltrexone induce development of veins and arteries in a proportional manner. In contrast, the angiogenic inhibitors OGF and retinoic acid demonstrated a greater inhibitory effect on arterial as compared with venous angiogenesis. Such differential effects on angiogenesis may be important in both defining mechanisms of action and designing therapeutic interventions.

Original languageEnglish (US)
Pages (from-to)532-538
Number of pages7
JournalJournal of Vascular Surgery
Volume35
Issue number3
DOIs
StatePublished - Jan 1 2002

Fingerprint

Naltrexone
Veins
Intercellular Signaling Peptides and Proteins
Chorioallantoic Membrane
Angiogenesis Inhibitors
Arteries
Vascular Endothelial Growth Factor A
Blood Vessels
Tretinoin
Growth
Methylcellulose
Enkephalins
Chick Embryo
vascular factor
Opioid Analgesics
Water

All Science Journal Classification (ASJC) codes

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

@article{e63440c6a17445e6b7c52f05dd50b52a,
title = "Differential effects of vascular growth factors on arterial and venous angiogenesis",
abstract = "Objective: Angiogenesis, the development of new blood vessels, has become an area of increased interest for both scientific and clinical application purposes. Proangiogenic agents, such as vascular endothelial growth factor (VEGF) and naltrexone, have been shown to effectively induce new blood vessel growth. Other growth factors, such as the endogenous opioid growth factor (OGF; [Mct5]-enkephalin) and retinoic acid, are inhibitors of angiogenesis. The differential effects on veins and arteries, however, by any vascular growth factor, have not previously been investigated. Methods: The chick chorioallantoic membrane (CAM) assay was used for the in vivo quantitation of angiogenesis. After 3 days of incubation, fertilized chick embryos were explanted, and a 3.2-mm methylcellulose disk containing either the known angiogenic stimulators VEGF (0.2 μg, 1.0 μg) or naltrexone (0.1 μg, 5.0 μg), or the angiogenic inhibitors OGF (1.0 μg, 5.0 μg) or retinoic acid (1.0 μg) was placed onto the CAM surface. An equal volume of distilled water served as a control. After 2 days of growth, the CAM arteries and veins were identified, and images were obtained with a digital camera. Quantitative analysis of angiogenesis was performed on a 100-mm2 area surrounding the applied disk, and the number and length of the veins and arteries were measured. Results: The angiogenic stimulators VEGF and naltrexone markedly increased both the total number and length of all blood vessels as compared with control values. The mean length of blood vessels decreased, suggesting the induction of new vessel growth. VEGF and naltrexone proportionately increased vein and arterial angiogenesis, maintaining artery/vein ratios for vessel number and length that were unchanged compared with controls. The angiogenic inhibitors, OGF and retinoic acid, notably decreased the total number and length of blood vessels in the CAM preparations. However, these compounds had a disproportionately greater inhibitory effect on arterial angiogenesis as reflected in decreased artery/vein ratios for vessel number and length. Conclusions: The angiogenic stimulators VEGF and naltrexone induce development of veins and arteries in a proportional manner. In contrast, the angiogenic inhibitors OGF and retinoic acid demonstrated a greater inhibitory effect on arterial as compared with venous angiogenesis. Such differential effects on angiogenesis may be important in both defining mechanisms of action and designing therapeutic interventions.",
author = "John Blebea and Vu, {Jonathan Hien} and Shahin Assadnia and Patricia McLaughlin and Robert Atnip and Ian Zagon",
year = "2002",
month = "1",
day = "1",
doi = "10.1067/mva.2002.120042",
language = "English (US)",
volume = "35",
pages = "532--538",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "3",

}

Differential effects of vascular growth factors on arterial and venous angiogenesis. / Blebea, John; Vu, Jonathan Hien; Assadnia, Shahin; McLaughlin, Patricia; Atnip, Robert; Zagon, Ian.

In: Journal of Vascular Surgery, Vol. 35, No. 3, 01.01.2002, p. 532-538.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differential effects of vascular growth factors on arterial and venous angiogenesis

AU - Blebea, John

AU - Vu, Jonathan Hien

AU - Assadnia, Shahin

AU - McLaughlin, Patricia

AU - Atnip, Robert

AU - Zagon, Ian

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Objective: Angiogenesis, the development of new blood vessels, has become an area of increased interest for both scientific and clinical application purposes. Proangiogenic agents, such as vascular endothelial growth factor (VEGF) and naltrexone, have been shown to effectively induce new blood vessel growth. Other growth factors, such as the endogenous opioid growth factor (OGF; [Mct5]-enkephalin) and retinoic acid, are inhibitors of angiogenesis. The differential effects on veins and arteries, however, by any vascular growth factor, have not previously been investigated. Methods: The chick chorioallantoic membrane (CAM) assay was used for the in vivo quantitation of angiogenesis. After 3 days of incubation, fertilized chick embryos were explanted, and a 3.2-mm methylcellulose disk containing either the known angiogenic stimulators VEGF (0.2 μg, 1.0 μg) or naltrexone (0.1 μg, 5.0 μg), or the angiogenic inhibitors OGF (1.0 μg, 5.0 μg) or retinoic acid (1.0 μg) was placed onto the CAM surface. An equal volume of distilled water served as a control. After 2 days of growth, the CAM arteries and veins were identified, and images were obtained with a digital camera. Quantitative analysis of angiogenesis was performed on a 100-mm2 area surrounding the applied disk, and the number and length of the veins and arteries were measured. Results: The angiogenic stimulators VEGF and naltrexone markedly increased both the total number and length of all blood vessels as compared with control values. The mean length of blood vessels decreased, suggesting the induction of new vessel growth. VEGF and naltrexone proportionately increased vein and arterial angiogenesis, maintaining artery/vein ratios for vessel number and length that were unchanged compared with controls. The angiogenic inhibitors, OGF and retinoic acid, notably decreased the total number and length of blood vessels in the CAM preparations. However, these compounds had a disproportionately greater inhibitory effect on arterial angiogenesis as reflected in decreased artery/vein ratios for vessel number and length. Conclusions: The angiogenic stimulators VEGF and naltrexone induce development of veins and arteries in a proportional manner. In contrast, the angiogenic inhibitors OGF and retinoic acid demonstrated a greater inhibitory effect on arterial as compared with venous angiogenesis. Such differential effects on angiogenesis may be important in both defining mechanisms of action and designing therapeutic interventions.

AB - Objective: Angiogenesis, the development of new blood vessels, has become an area of increased interest for both scientific and clinical application purposes. Proangiogenic agents, such as vascular endothelial growth factor (VEGF) and naltrexone, have been shown to effectively induce new blood vessel growth. Other growth factors, such as the endogenous opioid growth factor (OGF; [Mct5]-enkephalin) and retinoic acid, are inhibitors of angiogenesis. The differential effects on veins and arteries, however, by any vascular growth factor, have not previously been investigated. Methods: The chick chorioallantoic membrane (CAM) assay was used for the in vivo quantitation of angiogenesis. After 3 days of incubation, fertilized chick embryos were explanted, and a 3.2-mm methylcellulose disk containing either the known angiogenic stimulators VEGF (0.2 μg, 1.0 μg) or naltrexone (0.1 μg, 5.0 μg), or the angiogenic inhibitors OGF (1.0 μg, 5.0 μg) or retinoic acid (1.0 μg) was placed onto the CAM surface. An equal volume of distilled water served as a control. After 2 days of growth, the CAM arteries and veins were identified, and images were obtained with a digital camera. Quantitative analysis of angiogenesis was performed on a 100-mm2 area surrounding the applied disk, and the number and length of the veins and arteries were measured. Results: The angiogenic stimulators VEGF and naltrexone markedly increased both the total number and length of all blood vessels as compared with control values. The mean length of blood vessels decreased, suggesting the induction of new vessel growth. VEGF and naltrexone proportionately increased vein and arterial angiogenesis, maintaining artery/vein ratios for vessel number and length that were unchanged compared with controls. The angiogenic inhibitors, OGF and retinoic acid, notably decreased the total number and length of blood vessels in the CAM preparations. However, these compounds had a disproportionately greater inhibitory effect on arterial angiogenesis as reflected in decreased artery/vein ratios for vessel number and length. Conclusions: The angiogenic stimulators VEGF and naltrexone induce development of veins and arteries in a proportional manner. In contrast, the angiogenic inhibitors OGF and retinoic acid demonstrated a greater inhibitory effect on arterial as compared with venous angiogenesis. Such differential effects on angiogenesis may be important in both defining mechanisms of action and designing therapeutic interventions.

UR - http://www.scopus.com/inward/record.url?scp=0036518876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036518876&partnerID=8YFLogxK

U2 - 10.1067/mva.2002.120042

DO - 10.1067/mva.2002.120042

M3 - Article

VL - 35

SP - 532

EP - 538

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 3

ER -